Geulah Livshits
Stock Analyst at Chardan Capital
(4.33)
# 381
Out of 5,072 analysts
241
Total ratings
46.06%
Success rate
20.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geulah Livshits
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $82 → $74 | $53.47 | +38.40% | 16 | Nov 26, 2025 | |
| IMTX Immatics | Maintains: Buy | $25 | $10.69 | +133.86% | 3 | Nov 24, 2025 | |
| PVLA Palvella Therapeutics | Maintains: Buy | $110 | $102.79 | +7.01% | 5 | Nov 13, 2025 | |
| IMRX Immuneering | Maintains: Buy | $20 | $7.66 | +161.10% | 15 | Nov 13, 2025 | |
| PASG Passage Bio | Maintains: Buy | $6 → $21 | $8.93 | +135.16% | 6 | Nov 12, 2025 | |
| FDMT 4D Molecular Therapeutics | Maintains: Buy | $25 → $26 | $11.66 | +122.98% | 13 | Nov 11, 2025 | |
| TNYA Tenaya Therapeutics | Maintains: Buy | $9 | $1.40 | +542.86% | 13 | Nov 10, 2025 | |
| PRME Prime Medicine | Maintains: Buy | $10 → $9 | $3.82 | +135.60% | 7 | Nov 10, 2025 | |
| NTLA Intellia Therapeutics | Maintains: Buy | $48 → $26 | $8.99 | +189.21% | 17 | Nov 7, 2025 | |
| IOVA Iovance Biotherapeutics | Maintains: Buy | $20 → $17 | $2.47 | +588.26% | 15 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 | $9.86 | +72.41% | 12 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $4.74 | +153.16% | 16 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 | $5.43 | +176.24% | 9 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $216 → $220 | $218.00 | +0.92% | 14 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 | $3.42 | +221.64% | 22 | Oct 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $11 | $1.75 | +528.57% | 7 | Aug 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 | $2.23 | +438.12% | 10 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $6 | $0.55 | +1,000.31% | 6 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.41 | - | 10 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $41 | $8.30 | +394.27% | 4 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $12 | $2.57 | +366.93% | 4 | Mar 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $191 → $208 | $25.98 | +700.62% | 7 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $16 | $0.77 | +1,975.23% | 4 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $100 → $90 | $13.39 | +572.14% | 1 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $4 | $4.09 | -2.20% | 3 | Nov 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $50 → $30 | $4.12 | +628.16% | 1 | Jul 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $18.43 | -2.31% | 1 | Oct 27, 2020 |
CRISPR Therapeutics AG
Nov 26, 2025
Maintains: Buy
Price Target: $82 → $74
Current: $53.47
Upside: +38.40%
Immatics
Nov 24, 2025
Maintains: Buy
Price Target: $25
Current: $10.69
Upside: +133.86%
Palvella Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $110
Current: $102.79
Upside: +7.01%
Immuneering
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $7.66
Upside: +161.10%
Passage Bio
Nov 12, 2025
Maintains: Buy
Price Target: $6 → $21
Current: $8.93
Upside: +135.16%
4D Molecular Therapeutics
Nov 11, 2025
Maintains: Buy
Price Target: $25 → $26
Current: $11.66
Upside: +122.98%
Tenaya Therapeutics
Nov 10, 2025
Maintains: Buy
Price Target: $9
Current: $1.40
Upside: +542.86%
Prime Medicine
Nov 10, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.82
Upside: +135.60%
Intellia Therapeutics
Nov 7, 2025
Maintains: Buy
Price Target: $48 → $26
Current: $8.99
Upside: +189.21%
Iovance Biotherapeutics
Nov 6, 2025
Maintains: Buy
Price Target: $20 → $17
Current: $2.47
Upside: +588.26%
Nov 5, 2025
Maintains: Buy
Price Target: $17
Current: $9.86
Upside: +72.41%
Nov 5, 2025
Maintains: Buy
Price Target: $12
Current: $4.74
Upside: +153.16%
Nov 4, 2025
Maintains: Buy
Price Target: $15
Current: $5.43
Upside: +176.24%
Nov 4, 2025
Maintains: Buy
Price Target: $216 → $220
Current: $218.00
Upside: +0.92%
Oct 14, 2025
Maintains: Buy
Price Target: $11
Current: $3.42
Upside: +221.64%
Aug 15, 2025
Maintains: Buy
Price Target: $12 → $11
Current: $1.75
Upside: +528.57%
Aug 8, 2025
Maintains: Buy
Price Target: $12
Current: $2.23
Upside: +438.12%
May 16, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $0.55
Upside: +1,000.31%
Dec 13, 2024
Downgrades: Neutral
Price Target: n/a
Current: $2.41
Upside: -
Aug 11, 2023
Reiterates: Buy
Price Target: $41
Current: $8.30
Upside: +394.27%
Mar 22, 2023
Reiterates: Buy
Price Target: $12
Current: $2.57
Upside: +366.93%
Jan 18, 2023
Maintains: Neutral
Price Target: $191 → $208
Current: $25.98
Upside: +700.62%
Nov 15, 2022
Maintains: Buy
Price Target: $15 → $16
Current: $0.77
Upside: +1,975.23%
Nov 3, 2021
Maintains: Buy
Price Target: $100 → $90
Current: $13.39
Upside: +572.14%
Nov 3, 2021
Maintains: Neutral
Price Target: $5.5 → $4
Current: $4.09
Upside: -2.20%
Jul 23, 2021
Maintains: Neutral
Price Target: $50 → $30
Current: $4.12
Upside: +628.16%
Oct 27, 2020
Initiates: Buy
Price Target: $18
Current: $18.43
Upside: -2.31%